Boston BioProducts Receives ISO 13485:2016 Quality Certification
Boston BioProducts, a longstanding manufacturer of fundamental reagents for the life sciences, today announced that its quality management system (QMS) has achieved ISO 13485:2016 certification from TÜV SÜD America for the medical device manufacturing and supply of buffers, solutions, media, and reagents serving research, diagnostics, and therapeutics applications. Achieving this certification signifies Boston BioProducts’ commitment to high-quality standards across the entire reagent manufacturing process.
ISO 13485:2016 is considered the industry standard for QMS systems designed for medical devices and related services. It sets a robust and reproducible framework for the design, development, and manufacturing of products that meets customer and regulatory requirements. The International Organization for Standardization (ISO) is a global, independent publisher of standards governing the safety, reliability, and quality of manufactured products. TÜV SÜD America is among the most respected and accomplished certification bodies in the market serving thousands of registrations worldwide.
“This major company milestone further supports Boston BioProducts’ path to becoming a premier partner for contract reagent development and manufacturing across research, diagnostics, and therapeutics”, said Neil Sharma, General Manager of Boston BioProducts. “Scientists, assay developers, and manufacturing engineers can rely on a single source for the customization, testing, and supply of their process-critical buffers, solutions, and media reagents whether starting from innovation to publication, RUO to IVD, or preclinical to GMP.”
With the ISO 13485:2016 certification, Boston BioProducts is better positioned to support a range of growing regulated applications such as in vitro diagnostics, clinical trial assays , and cell and gene therapy manufacturing. This elevated quality management system complements the company’s flexible custom reagent manufacturing and rapid product delivery.
About Boston BioProducts
For nearly 30 years, Boston BioProducts (BBP) has manufactured and supplied fundamental reagents (buffers, solutions, media, and more) to researchers, diagnostic and technology platforms, and drug developers worldwide. With its custom reagent manufacturing services, BBP becomes an extension of your lab with flexible parameters to design the ideal research and manufacturing tools. Its mission is to increase the reproducibility of product- and process-critical reagents that keep your science consistent and moving forward. For more information, please visit www.bostonbioproducts.com and follow us on LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230406005030/en/
Contact information
Boston BioProducts Marketing
marketing@bostonbioproducts.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Empowering Excellence Through AI Enablement: HTEC Invests in a 100% AI-fluent Workforce8.5.2024 17:16:00 EEST | Press release
HTEC, a global digital consulting, software engineering, and product development firm, has launched an organization-wide AI enablement initiative. The initiative aims to equip HTEC’s global workforce with fundamental and highly technical artificial intelligence (AI) capabilities and provide continuing education in AI. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240508019530/en/ HTEC announces AI enablement program (Photo: Business Wire) Bringing each HTEC employee to the necessary level of AI literacy is crucial — it enables the organization to continue leading AI-powered digital transformations for its clients and ensure the productivity and effectiveness of its workforce while doing so. “To lead and transform our customers, we must transform ourselves. Prioritizing hands-on experience and continuous learning is necessary to stay ahead in AI. The HTEC AI Enablement program will seamlessly guide our teams into the new AI
Study Suggests Critical Link Between Residual FLT3-ITD Mutations in Remission and Post-Transplant Outcomes in AML8.5.2024 17:00:00 EEST | Press release
A groundbreaking research study,1 sequencing DNA samples from the Pre-MEASURE study2 strongly indicates that the detection of residual FLT3 internal tandem duplication (ITD) mutations in the blood of adult subjects with acute myeloid leukemia (AML) in first complete remission (CR) is associated with worse outcomes after post allogeneic hematopoietic cell transplant (HCT). This follow-up study performed measurable residual disease (MRD) testing on DNA of 537 subjects with FLT3-ITD AML from the Pre-MEASURE study using Invivoscribe’s RUO FLT3 ITD MRD Assay kit and bioinformatics software. Its findings underscore the likely significance of residual FLT3-ITD in first CR in predicting relapse and mortality post-transplant. A key finding from this research study was that AML subjects with residual FLT3-ITD detected prior to allogeneic HCT trended towards elevated risk of relapse and mortality post-transplant, with a dose-dependent correlation within this study population. Dr. Hourigan, Direct
RunPod Raises $20M in Seed Funding Co-led by Intel Capital and Dell Technologies Capital8.5.2024 16:07:00 EEST | Press release
RunPod, the launchpad that empowers developers to deploy custom full-stack AI applications, today announced it raised $20M in Seed funding, co-led by Intel Capital and Dell Technologies Capital with participation from Julien Chaummond, Nat Friedman, and Adam Lewis. In conjunction with the financing, Mark Rostick, Vice President and Senior Managing Director at Intel Capital, will join RunPod’s board of directors. RunPod is a globally distributed GPU cloud computing service for training, deploying, and scaling AI models. Using RunPod’s two core products, GPU Cloud and Serverless, developers can spin up an on-demand GPU instance in a few clicks and create autoscaling API endpoints for scaling inference on AI models in production. “The ability to create and deploy AI applications at scale will be paramount to their adoption and utilization,” said Amjad Masad, RunPod investor. “The RunPod team has clearly prioritized the developer experience to create an elegant solution that enables indivi
Tigo Energy Delivers Most Powerful Solar MLPE for High-Wattage and Bifacial Modules8.5.2024 16:00:00 EEST | Press release
Tigo Energy, Inc. (NASDAQ: TYGO), a leading provider of intelligent solar and energy software solutions, today announced the newest additions to the Tigo Flex MLPE product family, the Tigo TS4-X line. Designed to serve the commercial and industrial (C&I) as well as utility solar markets, Tigo TS4-X products support the latest high-power solar modules, up to 800W. Members of the TS4-X product family feature compatibility with Pure Signal™ technology in Tigo RSS Transmitters and offer a Multi-Factor Rapid Shutdown (MFRS) option with redundant safety signaling for solar systems serving the food and pharmaceutical cold-chain sectors, or other energy-critical applications. The new devices pair with an industry-leading list of third-party solar inverters to deliver design and installation flexibility for solar installers and engineering, procurement, and construction specialists (EPCs). As Levelized Cost Of Energy (LCOE) continues to drive the large-scale solar sectors, the TS4-X product lin
Cyolo Partners with Dragos to Unveil Holistic Secure Remote Access Solution for Critical Infrastructure8.5.2024 15:30:00 EEST | Press release
Cyolo, the secure remote access company for operational technology (OT) and industrial control systems (ICS), today announced a strategic partnership with Dragos, a global leader in cybersecurity for ICS/OT. Under the umbrella of Cyolo’s CyoloVerse partner program, Cyolo's PRO Secure Remote Access Platform will work with Dragos’s industry-leading OT cybersecurity platform. This collaboration will provide organizations with a robust and interoperable solution to protect their critical infrastructure against cyber threats. New technology implementations in ICS/OT environments pose unique risks for critical infrastructure. Today’s risks include lack of support for modern authentication or connectivity methods in traditional environments, connecting existing infrastructure with highly vulnerable end-of-life operating systems, or risk of breaches from third-party remote access. This interoperability is designed to provide OT customers visibility and management of their asset inventory and e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom